



compound according to any of Formulas XVIb1000-1002b, I-Ib, or X-XIXb-2, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein **Ar** is a divalent six-membered, substituted or unsubstituted, monocyclic aryl or heteroaryl ring. In an embodiment, provided herein is a compound according to any of Formulas XVIb1000-1002b, I-Ib, or X-XIXb-2, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein **Ar** is a divalent eight-, nine- or ten-membered, substituted or unsubstituted, fused bicyclic aryl, or fused heteroaryl ring. In an embodiment, provided herein is a compound according to any of Formulas XVIb1000-1002b, I-Ib, or X-XIXb-2, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein **Ar** is a divalent nine-membered, substituted or unsubstituted, fused bicyclic heteroaryl ring. In an embodiment, provided herein is a compound according to any of Formulas XVIb1000-1002b, I-Ib, or X-XIXb-2, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein **Ar** is phenylene or indolylene, each of which is unsubstituted or substituted. In an embodiment, provided herein is a compound according to any of Formulas XVIb1000-1002b, I-Ib, or X-XIXb-2, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein **Ar** is any of the following:




[00149] In an embodiment, provided herein is a compound according to any of Formulas XVIb1000-1002b, I-Ib, or X-XIXb-2, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein **L** is absent. In an embodiment, provided herein is a compound according to any of Formulas XVIb1000-1002b, I-Ib, or X-XIXb-2, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein **L** is –CH₂–.

[00150] In an embodiment, provided herein is a compound according to any of Formulas 1000-1002b and I-XIXb-2 in which the group “EG” is present in the formula, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein **EG** comprises phenylene, carboxylene, amino, or a combination thereof. In an embodiment, provided herein is a compound according to any of Formulas I 1000-1002b and I-XIXb-2 in

1. A compound according to Formula 1000:



L is absent or $-\text{CH}_2-$;




EG is absent or an eliminator group;

each **RT** is a release trigger group, in the backbone of Formula 1000 or bonded to **EG**, wherein each **RT** is optional;

RT¹ is a release trigger group, or a cleavable linker, or **RT¹** is absent;


HP is a single bond, absent, or a divalent hydrophilic group;



SG is a single bond, absent, or a divalent spacer group; and



R is hydrogen, or a terminal conjugating group.

2. The compound of Claim 1 according to Formula I:



or a pharmaceutically acceptable salt, solvate, or tautomer thereof, wherein **EG** is an eliminator group.

3. The compound of claim 1 according to Formula 1001 or 1002:





or a pharmaceutically acceptable salt, solvate, or tautomer thereof, wherein







RT¹ is a release trigger group or a cleavable linker;

RT is a release trigger group bonded to **EG**; and **RT** is optional;

R is hydrogen or a terminal conjugating group.


4. The compound of claim 1 or 2, according to any of Formulas II-IX:










or a pharmaceutically acceptable salt, solvate, or tautomer thereof, wherein one **RT** is optional.



5. The compound of claim 1 or 2, according to any of Formulas XI-XVI:






or a pharmaceutically acceptable salt, solvate, or tautomer thereof; wherein **m** is an integer selected from 1 to 12 and one **RT** is optional.


6. The compound of claim 1 or 3, according to any of the following Formula:




(III-1)




(IV-1)




(V-1)




(VI-1)




(VII-1)




(VIII-1)




(IX-1)




(II-2)




(III-2)




(IV-2)




(V-2)




(VI-2)



(VII-2)




(VIII-2)




(IX-2)

or a pharmaceutically acceptable salt, solvate, or tautomer thereof;








7. The compound of claim 1 or 3, according to any of the following Formulas:



(XI-1)





(XII-1)








8. The compound of any one of claims 1-7, wherein **R** comprises an alkyne, strained alkene, tetrazine, thiol, para-acetyl-phenylalanine residue, oxyamine, maleimide, carbonyl alkyl halide, aryl sulfide, or azide.






, -N₃, or -SH;

10. The compound of claim 9, wherein **R**²⁰¹ is methyl, ethyl, or propyl.

11. The compound of claim 9 or 10, wherein **R**²⁰¹ is methyl.

176


13. The compound of any one of claims 1-12, wherein **EG** is:



wherein each R^{EG} is independently selected from the group consisting of hydrogen, alkyl, biphenyl, $-CF_3$, $-NO_2$, $-CN$, fluoro, bromo, chloro, alkoxy, alkylamino, dialkylamino, alkyl- $C(O)O-$, alkylamino- $C(O)-$ and dialkylamino- $C(O)-$.


14. The compound of any one of claims 1-13, wherein **RT** comprises a residue of a natural or non-natural amino acid or a residue of a sugar.

15. The compound of any one of claims 1-14, wherein **RT** is:



16. The compound of any one of claims 1, 3, and 6-15, where RT^1 is a release trigger group, or a cleavable linker;


17. The compound of any one of claims 1, 3, and 6-16, wherein **RT**¹ is absent;



; valine-alanine; valine-glutamic acid; alanine-phenylalanine; phenylalanine-lysine; phenylalanine-homolysine; glycine-glycine-glycine; $\text{--}\text{HN--C}_1\text{--C}_6\text{--alkylene--C(O)--}$, $\text{--}\text{HN--C}_1\text{--C}_6\text{--alkylene--C(O)--aa--}$ where **aa** is a natural or non-natural amino acid residue; or $\text{--}\text{N--C(O)--}$ where the N--C(O) ring is a 4-7 membered heterocyclic ring comprising 3-6 carbon atoms.


18. The compound of any one of claims 1-17, wherein **SG** comprises $\text{C}_1\text{--C}_{10}$ alkylene, --C(O)-- , or a combination thereof.

19. The compound of any one of claims 1-18, wherein **SG** is:




20. The compound of any one of claims 1, 2, 4, 5, and 8-19, wherein **HP** comprises poly(ethylene glycol).

21. The compound of any one of claims 1, 2, 4, 5, and 8-20, wherein **HP** is:



wherein **m** is an integer selected from 1 to 12.


22. The compound of any one of claims 1, 3, and 6-19, wherein **HP**¹ is absent or




where **R**^{HP} is R-- where **R** is --H or --CH_3 and **m** is an integer selected from 1 to 12 or **R**^{HP} is $\text{--C}_1\text{--C}_6\text{--alkylene--SO}_3$.

23. The compound of any one of claims 1-22, wherein **W**¹, **W**², **W**³, **W**⁴, and **W**⁵ are each independently a single bond, absent, or comprise --C(O)-- , --O-- , --C(O)NH-- , --C(O)NH--alkyl-- , --OC(O)NH-- , --SC(O)NH-- , --NH-- , --NH--alkyl-- , $\text{--N(CH}_3\text{)CH}_2\text{CH}_2\text{N(CH}_3\text{)--}$, --S-- , --S--S-- , $\text{--OCH}_2\text{CH}_2\text{O--}$, or a combination thereof.


24. The compound of any one of claims 1-23 where **W**¹, **W**², **W**³, **W**⁴, and **W**⁵ are independently absent or a bond; or a pharmaceutically acceptable salt, solvate, or tautomer thereof.
25. The compound of any one of claims 1-3, 5, and 7-24, wherein **Ar** is a divalent six-membered, substituted or unsubstituted, monocyclic aryl or heteroaryl ring.
26. The compound of any one of claims 1-3, 5, and 7-25, wherein **Ar** is a divalent six-membered substituted or unsubstituted, monocyclic aryl, or a divalent six-membered, substituted or unsubstituted, heteroaryl.
27. The compound of any one of claims 1-3, 5, and 7-24, wherein **Ar** is a divalent six-membered substituted or unsubstituted, monocyclic aryl, or a divalent eight-, nine- or ten-membered, substituted or unsubstituted, fused bicyclic heteroaryl.
28. The compound of any one of claims 1-3, 5, 7-24, and 27, wherein **Ar** is a divalent nine-membered, substituted or unsubstituted, fused bicyclic heteroaryl.
29. The compound of any one of claims 1-3, 5, and 7-24, wherein **Ar** is any one of the following:




30. The compound of any one of claims 1-3, 5, and 7-29, wherein **L** is absent.
31. The compound of any one of claims 1-3, 5, and 7-29, wherein **L** is $-\text{CH}_2-$.
32. The compound of any one of claims 1, 2, and 4, wherein **W**¹, **W**², **W**³, **W**⁴, **W**⁵, **EG**, **RT**, **HP**, **SG**, and **R** combine to form $-\text{H}$.
33. The compound of claim 1, according to any one of the following Formula:




(101)




(102)




(103)




(104)




(105)




(106)




(107)




(108)











(109)



(110)




(111)



or a pharmaceutically acceptable salt, solvate, or tautomer thereof.

34. A conjugate comprising a residue of the compound of any one of claims 1-33, or a pharmaceutically acceptable salt, solvate, or tautomer thereof, linked to a second compound.

35. The conjugate of claim 34 according to Formula (E1):




or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein:

COMP is a residue of a second compound;

Ar is a divalent six-membered substituted or unsubstituted, monocyclic aryl, a divalent five- or six-membered, substituted or unsubstituted, heteroaryl or a divalent eight-, nine- or ten-membered, substituted or unsubstituted, fused heteroaryl;

L is absent or $-\text{CH}_2-$;




W¹, **W²**, **W³**, **W⁴**, and **W⁵** are each independently a single bond, absent, or a divalent attaching group;

EG is absent or an eliminator group;

each **RT** is a release trigger group, in the backbone of Formula E1 or bonded to **EG**, wherein **RT** is optional;

RT¹ is a release trigger group, or a cleavable linker, or **RT¹** is absent;


HP is a single bond, absent, or a divalent hydrophilic group;

HP¹ is a single bond, absent, a divalent hydrophilic group, or  where **R^{HP}** is a monovalent hydrophilic group;

SG is a single bond, absent, or a divalent spacer group; and



R''' is a divalent residue of a terminal conjugating group.







36. The conjugate of claim 35, according to Formula C1:



or a pharmaceutically acceptable salt, solvate, or tautomer thereof, wherein **EG** is an eliminator group; and each **RT** is a release trigger group, and one **RT** is optional.


37. The conjugate of claim 35 or 36 according to any one of Formulas C2-C9:








or a pharmaceutically acceptable salt, solvate, or tautomer thereof wherein one **RT** is optional.





38. The conjugate of claim 35 or 36 according to any one of Formulas C10-C13:







or a pharmaceutically acceptable salt, solvate, or tautomer thereof, wherein **m** is an integer selected from 1 to 12 and one **RT** is optional.

39. The conjugate of claim 35 or 36 according to any one of Formulas C14-C17:



or a pharmaceutically acceptable salt, solvate, or tautomer thereof, wherein one **RT** is optional.

40. The conjugate of claim 35 according to Formula (F1) or (G1):















or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein:





RT¹ is a release trigger group or a cleavable linker group; and

RT is a release trigger group bonded to **EG**; wherein **RT** is optional.

41. The conjugate of claim 35 or 40 according to any one of the following Formulas:













or a pharmaceutically acceptable salt, solvate, or tautomer thereof wherein **RT** is optional.





42. The conjugate of claim 35 or 40 according to any one of the following Formulas:







or a pharmaceutically acceptable salt, solvate, or tautomer thereof, wherein **m** is an integer selected from 1 to 12 and **RT** is optional.

43. The conjugate of claim 35 or 40 according to any one of the following Formulas:







(G14)



(G15)



(G16)




(G17)

or a pharmaceutically acceptable salt, solvate, or tautomer thereof, wherein **RT** is optional.

44. The conjugate of any one of claims 35-43, wherein **EG** comprises phenylene, carboxylene, amino, or a combination thereof.


45. The conjugate of any one of claims 35-44, wherein **EG** is:




wherein each R^{EG} is independently selected from the group consisting of hydrogen, alkyl, biphenyl, $-CF_3$, $-NO_2$, $-CN$, fluoro, bromo, chloro, alkoxy, alkylamino, dialkylamino, alkyl- $C(O)O-$, alkylamino- $C(O)-$ and dialkylamino- $C(O)-$.

46. The conjugate of any one of claims 35-45, wherein **RT** comprises a residue of a natural or non-natural amino acid or a residue of a sugar.

47. The conjugate of any one of claims 35-46, wherein **RT** is:



48. The conjugate of any one of claims 35 and 40-47, wherein **RT¹** is absent;




; valine-alanine; valine-glutamic acid; alanine-phenylalanine; phenylalanine-lysine; phenylalanine-homolysine; glycine-glycine-glycine;

$\text{--}\ddot{\text{N}}\text{--C}_1\text{--C}_6\text{--alkylene--C(O)--}\ddot{\text{N}}\text{--}$; $\text{--}\ddot{\text{N}}\text{--C}_1\text{--C}_6\text{--alkylene--C(O)--aa--}\ddot{\text{N}}\text{--}$ where **aa** is a natural or non-natural amino acid residue; or $\text{--}\ddot{\text{N}}\text{--}\bigcirc\text{--C(O)--}\ddot{\text{N}}\text{--}$ where the $\bigcirc$ ring is a 4-7 membered heterocyclic ring comprising 3-6 carbon atoms.


49. The conjugate of any one of claims 35-48, wherein **SG** comprises $\text{C}_1\text{--C}_{10}$ alkylene, $\text{C}_4\text{--C}_6$ alkylene, --C(O)-- , or combination thereof.

50. The conjugate of any one of claims 35-49, wherein **SG** is:



51. The conjugate of any of claims 35-39 and 44-50, wherein **HP** comprises poly(ethylene glycol).

52. The conjugate of any one of claims 35-39 and 44-51, wherein **HP** is:



wherein **m** is an integer selected from 1 to 12.

53. The conjugate of any one of claims 35, 40-43, and 44-50, wherein **HP**¹ is absent

or where **R**^{HP} is wherein **R** is --H or --CH_3 and **m** is an integer selected from 1 to 12 or **R**^{HP} is $\text{--C}_1\text{--C}_6\text{--alkylene--SO}_3^-$.

54. The conjugate of any one of claims 35-53, wherein **W**¹, **W**², **W**³, **W**⁴, and **W**⁵ are each independently a single bond, absent, or comprise --C(O)-- , --O-- , --C(O)NH-- , --C(O)NH-alkyl-- , --OC(O)NH-- , --SC(O)NH-- , --NH-- , --NH-alkyl-- , $\text{--N(CH}_3\text{)CH}_2\text{CH}_2\text{N(CH}_3\text{)--}$, --S-- , --S--S-- , $\text{--OCH}_2\text{CH}_2\text{O--}$, or a combination thereof.


55. The conjugate of any one of claims 35, 36, 38-40, and 42-54, wherein **Ar** is a divalent six-membered substituted or unsubstituted, monocyclic aryl, or a divalent five- or six-membered, substituted or unsubstituted, heteroaryl.

56. The conjugate of any one of claims 35, 36, 38-40, and 42-55, wherein **Ar** is a divalent six-membered substituted or unsubstituted, monocyclic aryl, or a divalent six-membered, substituted or unsubstituted, heteroaryl.

57. The conjugate of any one of claims 35, 36, 38-40, and 42-54, wherein **Ar** is a divalent eight-, nine- or ten-membered, substituted or unsubstituted, fused bicyclic heteroaryl.

58. The conjugate of any one of claims 35, 36, 38-40, 42-54, and 57, wherein **Ar** is a divalent nine-membered, substituted or unsubstituted, fused bicyclic heteroaryl.


59. The conjugate of any one of claims 35, 36, 38-40, and 42-54, wherein **Ar** is any of the following:



60. The conjugate of any one of claims 35, 36, 38-40, and 42-59, wherein **L** is absent.

61. The conjugate of any one of claims 36, 38-40, and 42-59, wherein **L** is $-\text{CH}_2-$.

62. The conjugate of any one of claims 35-61-, wherein **R** is:



63. The conjugate of any one of claims 35-62, wherein **COMP** is a residue of a polypeptide.

64. The conjugate of any one of claims 35-62, wherein **COMP** is a residue of an antibody.

65. The conjugate of any one of claims 35-62, wherein **COMP** is a residue of an antibody chain.

66. A pharmaceutical composition comprising the compound of any one of claims 1-33 or conjugate of any one of claims 34-65; and a pharmaceutically acceptable excipient, carrier, or diluent.

67. The compound of any one of claims 1-33, conjugate of any one of claims 34-65, or pharmaceutical composition of claim 66 for use in therapy.


68. Use of an effective amount of the compound of any one of claims 1-33, conjugate of any one of claims 34-65, or pharmaceutical composition of claim 66 in the manufacture of a medicament for treating cell proliferation or cancer.

69. The use of claim 68 where the cancer is small cell lung cancer, non-small cell lung cancer, ovarian cancer, platinum-resistant ovarian cancer, ovarian adenocarcinoma, endometrial cancer, breast cancer, breast cancer which overexpresses Her2, triple-negative breast cancer, a lymphoma, large cell lymphoma; diffuse mixed histiocytic and lymphocytic lymphoma; follicular B cell lymphoma, colon cancer, colon carcinoma, colon adenocarcinoma, colorectal adenocarcinoma, melanoma, prostate cancer, or multiple myeloma.

70. A method of producing a conjugate, comprising contacting the compound of any one of claims 1-33 with a second compound under conditions suitable for conjugating the compound of any one of claims 1-33 with the second compound; wherein the second compound comprises an alkyne, strained alkene, tetrazine, thiol, maleimide, carbonyl, oxyamine, or azide.


71. The method of claim 70, wherein the second compound comprises a tetrazine; and **R** comprises a strained alkene.

72. The method of claim 70 or 71, wherein **R** is:



73. The method of claim 70, wherein the second compound comprises an azide; and **R** comprises an alkyne.

74. The method of claim 70 or 73, wherein **R** is:




75. The method of claim 70, wherein the second compound comprises an alkyne; and **R** comprises an azide.

76. The method of claim 70, wherein the second compound comprises a strained alkene; and **R** comprises a tetrazine.


77. The method of claim 70, wherein the second compound comprises a thiol; and **R** comprises a maleimide.

78. The method of claim 70 or 77, wherein **R** is:




79. The method of claim 70, wherein the second compound comprises a maleimide; and **R** comprises a thiol.

80. The method of claim 70 or 79, wherein the second compound comprises:




81. The method of claim 70, wherein the second compound comprises a carbonyl; and **R** comprises an oxyamine.

82. The method of claim 70 or 81, wherein **R** is:




83. The method of claim 70, 81, or 82, wherein second compound comprises:




84. The method of claim 70, wherein the second compound comprises an oxyamine; and **R** comprises a carbonyl.

85. The method of claim 70 or 84, wherein **R** is:



86. The method of claim 70, 84, or 85, wherein the second compound comprises:



87. The method of any one of claims 70-86, wherein the second compound is a polypeptide.

88. The method of any one of claims 70-86, wherein the second compound is an antibody

89. The method of any one of claims 70-86, wherein the second compound is an antibody chain.